We provide you with 20 years of free, institutional-grade data for CYCC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CYCC. Explore the full financial landscape of CYCC stock.
| Reported Date | CIK | Ticker | Type |
|---|
Cyclacel Pharmaceuticals, Inc(NASDAQ:CYCC) 
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial f...
Website: http://www.cyclacel.com
Founded: 1996
Full Time Employees: 12
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about CYCC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.